Serratus Posterior Superior Intercostal Plane BlockNCT06997601
Serratus Posterior Superior Intercostal Plane Block Versus Suprascapular Nerve Block and Axillary Nerve Block for Analgesia in Shoulder Arthroscopic Surgery
A study testing Serratus posterior superior intercostal plane block and Suprascapular nerve block + Axillary nerve block in people with Serratus Posterior Superior Intercostal Plane Block and Suprascapular Nerve Block, run by Tanta University at 1 site in Egypt.
Trial summary
This study aims to compare the serratus posterior superior intercostal plane block and suprascapular nerve block and axillary nerve block for analgesia in shoulder arthroscopic surgery. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Serratus Posterior Superior Intercostal Plane Block, Suprascapular Nerve Block, Axillary Nerve Block
- What is being tested?
- Serratus posterior superior intercostal plane block and Suprascapular nerve block + Axillary nerve block
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteEgypt
- Study dates
- 31 May 2025to 1 Nov 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age from 18 to 65 years.
- Both sexes.
- American Society of Anesthesiology (ASA) physical status I-II.
- Scheduled for open thoracotomy.
Who cannot join
- Infection at the site of regional blocks.
- Allergy to any drug used in this study.
- Use of psychotropic and/or narcotic medications on a regular basis.
- Cognitive dysfunction.
- Cardiovascular disease.
- Pulmonary disease.
Show all 12Show fewer
- Coagulation abnormalities.
- Anatomical abnormalities.
- Neuropathic pain.
- Body mass index >40.
- History of substance abuse.
- Previous surgery in the same shoulder.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Serratus Posterior Superior Intercostal Plane Block Versus Suprascapular Nerve Block and Axillary Nerve Block for Analgesia in Shoulder Arthroscopic Surgery: A Randomized Clinical Trial
This study aims to compare the serratus posterior superior intercostal plane block and suprascapular nerve block and axillary nerve block for analgesia in shoulder arthroscopic surgery.
Read the detailed description
Controlling postoperative pain while minimizing opioid administration is particularly important because poor pain control is thought to be responsible for more than 60% of unplanned or prolonged hospitalizations.
Suprascapular nerve block (SSNB) has been proposed based on the anatomic fact that the suprascapular nerve innervates approximately 70% of the shoulder joint, capsule, subacromial space, acromioclavicular joint, and coracoacromial ligament, with the remaining 30% thought to be innervated by the lateral pectoral and axillary nerve.
The combined SSNB and axillary nerve block (ANB) was proposed as a safe alternative to interscalene brachial plexus block (ISB) for providing anesthesia and postoperative analgesia for shoulder surgery.
Serratus posterior superior intercostal plane block (SPSIPB) was described as a novel technique in a case series study of cadavers and five patients.
- Conditions
- Serratus Posterior Superior Intercostal Plane Block, Suprascapular Nerve Block, Axillary Nerve Block, Analgesia, Shoulder Arthroscopic Surgery
- Being tested
- Serratus posterior superior intercostal plane block, Suprascapular nerve block + Axillary nerve block
- Medical subject headings
- Agnosia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Serratus posterior superior intercostal plane blockOther
Patients will receive a serratus posterior superior intercostal plane block.
Suprascapular nerve block + Axillary nerve blockOther
Patients will receive suprascapular nerve block + axillary nerve block.
| Study group | Role | What they receive |
|---|---|---|
| Group SPSIPB | Experimental | Patients will receive a serratus posterior superior intercostal plane block. Receives: Other: Serratus posterior superior intercostal plane block |
| Group SSSB+ANB | Experimental | Patients will receive suprascapular nerve block + axillary nerve block. Receives: Other: Suprascapular nerve block + Axillary nerve block |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to the 1st rescue analgesia
Time to the first request for the rescue analgesia (time from end of surgery to first dose of morphine administered).
Measured: 24 hours postoperatively
Secondary outcomes (4)
Degree of pain
Each patient will be instructed about postoperative pain assessment with the numeric rating scale (NRS) score. NRS (0 represents "no pain" while 10 represents "the worst pain imaginable"). NRS will be assessed at 0, 2, 4, 6, 8, 12, 18, and 24 h postoperatively.
Measured: 24 hours postoperatively
Intraoperative fentanyl consumption
Additional fentanyl bolus dosages of 1 µg/kg IV will be administered if the heart rate or mean arterial blood pressure is elevated by more than 20% of the baseline.
Measured: Intraoperatively
Total morphine consumption
Rescue analgesia of morphine will be given as 3 mg bolus if the numeric rating scale (NRS)> 3 to be repeated after 30 min if pain persists until the NRS < 4.
Measured: 24 hours postoperatively
Incidence of adverse events
Incidence of adverse events such as bradycardia, hypotension, nausea, vomiting, respiratory depression, or any other complication.
Measured: 24 hours postoperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 May 2025
- Study start31 May 2025
- Primary completion1 Nov 2025
- Study completion1 Nov 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Serratus Posterior Superior Intercostal Plane BlockStudies of the same condition, open and under way.
- More trials run by Tanta UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tanta University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohammed Said ElSharkawy, Tanta University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06997601
- Sponsor's protocol ID
- 36264PR1191/4/25
- Status last verified
- Nov 2025
- First submitted
- 21 May 2025
- Last updated
- 25 Nov 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Study at a glance
From the registry record, last updated by the sponsor on 25 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Serratus Posterior Superior Intercostal Plane Block Versus Suprascapular Nerve Block and Axillary Nerve Block for Analgesia in Shoulder Arthroscopic Surgery: A Randomized Clinical Trial
- ClinicalTrials.gov ID
- NCT06997601
- Acronym / sponsor ID
- 36264PR1191/4/25
- Conditions
- Serratus Posterior Superior Intercostal Plane Block, Suprascapular Nerve Block, Axillary Nerve Block, Analgesia, Shoulder Arthroscopic Surgery
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 50 participants (actual)
- Lead sponsor
- Tanta UniversityUniversity, hospital or other
- Study start
- 31 May 2025 (actual)
- Primary completion
- 1 Nov 2025 (actual)
- Study completion
- 1 Nov 2025 (actual)
- First posted
- 30 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to compare the serratus posterior superior intercostal plane block and suprascapular nerve block and axillary nerve block for analgesia in shoulder arthroscopic surgery.
Detailed description
Controlling postoperative pain while minimizing opioid administration is particularly important because poor pain control is thought to be responsible for more than 60% of unplanned or prolonged hospitalizations.
Suprascapular nerve block (SSNB) has been proposed based on the anatomic fact that the suprascapular nerve innervates approximately 70% of the shoulder joint, capsule, subacromial space, acromioclavicular joint, and coracoacromial ligament, with the remaining 30% thought to be innervated by the lateral pectoral and axillary nerve.
The combined SSNB and axillary nerve block (ANB) was proposed as a safe alternative to interscalene brachial plexus block (ISB) for providing anesthesia and postoperative analgesia for shoulder surgery.
Serratus posterior superior intercostal plane block (SPSIPB) was described as a novel technique in a case series study of cadavers and five patients.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group SPSIPB | Experimental | Other: Serratus posterior superior intercostal plane blockPatients will receive a serratus posterior superior intercostal plane block. |
| Group SSSB+ANB | Experimental | Other: Suprascapular nerve block + Axillary nerve blockPatients will receive suprascapular nerve block + axillary nerve block. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age from 18 to 65 years.
- Both sexes.
- American Society of Anesthesiology (ASA) physical status I-II.
- Scheduled for open thoracotomy.
Key exclusion criteria (12 listed)
- Infection at the site of regional blocks.
- Allergy to any drug used in this study.
- Use of psychotropic and/or narcotic medications on a regular basis.
- Cognitive dysfunction.
- Cardiovascular disease.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Serratus posterior superior intercostal plane blockPatients will receive a serratus posterior superior intercostal plane block. | Other | Group SPSIPB |
| Suprascapular nerve block + Axillary nerve blockPatients will receive suprascapular nerve block + axillary nerve block. | Other | Group SSSB+ANB |
Primary outcome
Time to the 1st rescue analgesia
Time frame: 24 hours postoperatively
Time to the first request for the rescue analgesia (time from end of surgery to first dose of morphine administered).
4 secondary outcomes
Degree of pain
Time frame: 24 hours postoperatively
Intraoperative fentanyl consumption
Time frame: Intraoperatively
Total morphine consumption
Time frame: 24 hours postoperatively
Incidence of adverse events
Time frame: 24 hours postoperatively
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Nov 2025.
- Individual participant dataSharing planned: Yes. The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Related trials for Serratus Posterior Superior Intercostal Plane Block
Not yet recruiting
Comparison of Serratus Posterior Superior Intercostal Plane Block and Rhomboid Intercostal Block in Patients Undergoing Breast Cancer Surgery
Breast Cancer, Lymph Node Dissection
Recruiting
Ultrasound-Guided Serratus Posterior Superior Intercostal Plane Block for Analgesia in Arthroscopic Shoulder Surgery
Postoperative Pain, Acute, Shoulder Pain
RecruitingObservational study
Pain Control and Recovery After Thoracic Surgery Using SPSIP Block
Postoperative Pain
Not yet recruiting
ESP Versus SPSIP Block for Pain Relief After Shoulder Arthroscopy
Postoperative Pain
Recruiting
Comparison of Postoperative Analgesic Efficacy of Two Different Blocks in Modified Radical Mastectomy Surgery
Breast Cancer, Postoperative Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Serratus posterior superior intercostal plane block and Suprascapular nerve block + Axillary nerve block in people with Serratus Posterior Superior Intercostal Plane Block and Suprascapular Nerve Block, run by Tanta University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to the 1st rescue analgesia (time frame: 24 hours postoperatively). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Nov 2025.